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Abstract
Hepatocellular carcinoma (HCC) is currently one of the top lethal cancers with an increasing
trend. Deregulation of MYC in HCC is frequently detected and always correlated with poor
prognosis. As the zebrafish genome contains two differentially expressed zebrafishmyc
orthologs,myca andmycb, it remains unclear about the oncogenicity of the two zebrafish
myc genes. In the present study, we developed two transgenic zebrafish lines to over-
expressmyca andmycb respectively in the liver using a mifepristone-inducible system and
found that both myc genes were oncogenic. Moreover, the transgenic expression ofmyca
in hepatocytes caused robust liver tumors with several distinct phenotypes of variable se-
verity. ~5% ofmyca transgenic fish developing multinodular HCC with cirrhosis after
8 months of inducedmyca expression. Apoptosis was also observed withmyca expression;
introduction of homozygous tp53-/-mutation into themyca transgenic fish reduced apopto-
sis and accelerated tumor progression. The malignant status of hepatocytes was depen-
dent on continued expression ofmyca; withdrawal of the mifepristone inducer resulted in a
rapid regression of liver tumors, and the tumor regression occurred even in the tp53-/-muta-
tion background. Thus, our data demonstrated the robust oncogenicity of zebrafishmyca
and the requirement of sustained Myc overexpression for maintenance of the liver tumor
phenotype in this transgenic model. Furthermore, tumor regression is independent of the
function of Tp53.
Introduction
Hepatocellular carcinoma (HCC), malignancy of hepatocytes, is the most common primary
liver cancer in Central/Southeast Asia and sub-Saharan Africa [1]. As a deadly tumor with the
traits of late-stage diagnosis, poor therapeutic response and bleak prognosis, it is a research hot
spot for oncologists and other scientists. In humans, HCC is associated with multiple risk fac-
tors, such as hepatitis virus infection, aflatoxin, alcohol abuse, and non-alcoholic steatohepati-
tis, which ultimately increase genome instability and transform hepatocytes into a neoplastic
state by cumulative mutations. Myc, a transcription factor which is estimated to regulate the
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expression of about 15% of cellular genes, is well known for its participation in many malignant
conversions [2].MYC gene amplification has also been frequently detected in human HCC
and is especially related to advanced HCC cases [3, 4].
To understand the fundamental mechanisms underlying cancer for developing effective
therapies, it is important to investigate tumor biology in animal models [5]. The zebrafish
(Danio rerio) has now emerged as a promising animal model for cancers because of its small
size, high fertility, well developed experimental resources and tools, and low maintenance costs
[6]. As vertebrate species, both zebrafish and human have many conserved anatomical struc-
tures and homologous organs with similar physiological functions. Zebrafish can develop a
wide spectrum of tumors in almost every tissue, which greatly resemble human malignancies
in both histological characteristics and gene expression profiles [7–10]. Our previous study re-
vealed that transgenic expression of mouseMyc in zebrafish lead to liver tumors [11] and an-
other study also reported liver hyperplasia in medaka caused by transgenic expression of a
quite divergent medaka myc gene [12]; however, so far no study has documented the oncoge-
nicity of zebrafishmyc. Due to the whole genome duplication occurred during fish evolution
following divergence of the teleost and tetrapod lineages, the zebrafish genome contains two
myc genes orthologous to humanMYC, i.e.myca andmycb [13]. In this study we generated
two zebrafish transgenic lines with induciblemyca andmycb expression, respectively, and
found that bothmyc paralogs were oncogenic in hepatocytes. Especially, overexpression of
myca resulted in high grade HCC with histological traits similar to human HCC cases and in-
troducing tp53 null mutation to the transgenic fish accelerated liver tumor progression. Fur-
thermore, the tumor status was addicted to constant overexpression ofmyca and suppression
of transgenicmyca expression by removal of the chemical inducer resulted in rapid tumor re-
gression even in the tp53-/- background.
Results
Bothmyca andmycb are oncogenic
To investigate the oncogenicity of the two zebrafishmyc paralogs, two effector transgenic zeb-
rafish lines carrying GFP fusedmyca andmycb, respectively, were generated. They were then
crossed with the liver-driver line [14] to obtain two double transgenic lines, named mycAG
and mycBG respectively for GFP fused myca and mycb. The constructs used for these trans-
genic lines are illustrated in S1 Fig. and the transgenic system has been described previously for
liver-specifically inducible krasv12 expression [14] based on the mifepristone inducible LexPR
system [15].
To examine the effects of myc gene expression, mycAG and mycBG fish were induced with
mifepristone of different concentrations from 1 month postfertilization (mpf) and sacrificed at
2 month post-induction (mpi) or 3 mpf. The expression of transgenicmycAG andmycBG was
increased with mifepristone concentrations, as manifested by the increased GFP fluorescence
in Fig. 1C2–C7 as well as by RT-qPCR (S2A Fig.). Moreover, the overexpression of mycAG
and mycBG resulted in overgrowth of liver (Fig. 1, B2–B7), as illustrated by GFP expression
(Fig. 1, C2–C7) and also as evident from the enlarged belly (Fig. 1, A2–A7), compared to the
liver in the Driver control that had only GFP expression in the liver (Fig. 1, A1, B1, C1 and S1
Fig.). Significant liver overgrowth was observed even in the case of weak expression with 0.005
μMmifepristone. Notably, the tumor size of the mycAG transgenic fish was significantly larger
than that of the mycBG fish while the body length was much smaller, indicating a higher
tumor burden in the mycAG fish.
Histological examination of mifepristone-induced Driver control fish showed that GFP ex-
pression has no impact on normal liver architecture and histology (Fig. 1, D1). In contrast, the
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liver of mycAG fish distinguished itself from normal histology with basophilic cytoplasm and
enlarged eosinophilic nucleoli (Fig. 1, D2, D4 and D6). With increasing mifepristone concen-
trations, the liver lesions in mycAG fish progressed from hyperplasia to hepatocellular adeno-
ma. In comparison, the tumor progression in mycBG fish was slow. At 0.005 μMmifepristone,
increased mitosis was observed in mycBG fish. Although aberrant nuclei were observed, the he-
patocytes retained eosinophilic cytoplasm and two-cell-thick plate organization was similar to
that observed in the Driver control (Fig. 1, D3). However, the nucleus abnormality was in-
creased with mifepristone concentration. At 4 μMmifepristone induction, the mycBG fish dis-
played liver hyperplasia (Fig. 1, D7) similar to that of the mycAG fish at 0.005 μM induction
(Fig. 1, D2).
The above findings confirmed that bothmyca andmycb were oncogenic in zebrafish hepato-
cytes. The difference in tumor status between the two myc transgenic lines may be attributed to
different levels of transgenic expression, which was confirmed by RT-qPCR analyses in S2A
Fig., where transgenicmycAG expression was almost 5 fold ofmycBG expression. There was a
dosage-dependent induction of GFP expression with increasing mifepristone concentrations
(S2C Fig.), confirmed by RT-qPCR (S2D Fig.), and noticeable increase of liver size based on 2D
image measurement (S2E Fig.). This was also consistent with the generally higher GFP intensity
in induced mycAG fish than mycBG fish in both fry (S2C Fig.) and adult (Fig. 1, C2–C7). Our
Figure 1. Liver tumor progression in mycAG andmycBG fish.MycAG fish and mycBG fish were induced with mifepristone of increasing concentrations,
as indicated at the top of the figure, from 1 mpf and sacrificed at 2 mpi (3 mpf). (A1–A7) Exterior observation of fish from each treatment group. (B1–B7) Gross
observation of liver tumors after removal of abdominal wall. (C1 to C7) The same views as those in (B1–B7) for observation of GFP expression that illustrate
the shape of livers. In B2 and C2, images from uninduced mycAG fish are included as insets for comparison and there were no enlarged liver (B2) and no
visible GFP expression in the liver although green fluorescent signals was observed in the gut in some fish (C2). (D1–D7) H&E staining of liver sections.
doi:10.1371/journal.pone.0117249.g001
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RT-qPCR data also confirmed that bothmycAG andmycBG expression were much higher than
endogenousmyca andmycb expression (S2A Fig.). Nuclear localization of both mycAG and
mycBG fusion proteins were observed and these Myc-localized nuclei were significantly larger
than these in the wild type and Driver controls, indicating pathological changes of these cells
(S2B Fig.). Collectively, these observations suggest a correlation of severity of neoplasia with the
level of myc mRNA expression.
Transgenic expression ofmycAG induces rapid liver tumors
accompanied with increased proliferation and apoptosis
As tumor progression in the mycAG line was faster and more severe than that in the mycBG
line, the mycAG fish provided a more robust platform for further characterization of Myc-
induced liver tumors and thus were used in the subsequent experiments. MycAG fish were in-
duced with 2 μMmifepristone from 1 mpf and sampled at different time points. As shown in
Fig. 2, A2, B2 and C2, although the liver size was still comparable with control, transformed he-
patocytes with basophilic hepatocytes and distinct eosinophilic nuclei had already emerged at
10 dpi (day post-induction). From 20 dpi, all the hepatocytes had been transformed (Fig. 2,
C3–C4). Moreover, the sinusoids were dilated in fast tumor progression and formed pseudo-
glandular phenotype with apparent ascites, as shown in Fig. 2C4 and S3 Fig.
Increased proliferation was also observed during tumor progression in the mycAG fish, as
demonstrated by the PCNA staining in Fig. 2D1–D4 and 2E. Usually, apoptosis serves as a bar-
rier in tumor progression; however, interestingly, apoptosis was also observed to increase in
the liver tumors of mycAG fish, as revealed by TUNEL assay in Fig. 2E1–E4 and 2F. This is
also consistent with some previous observations that Myc deregulation caused apoptosis
[16–18] and this property may serves as a safeguard in normal conditions and impedes myc de-
regulation-caused tumor initiation.
Variable levels of mycAG expression results in different types of liver
tumors
At 1 mpi, the majority (~87%) of induced mycAG fish showed ascites-like phenotype with yel-
low fluid in abdomen cavity as well as fluid-filled cysts in the liver. With the tumor progression,
ascites gradually decreased in many of the mycAG fish and the relatively uniform pseudogland-
ular tumor type turned into divergent phenotypes. As indicated in Fig. 3, in 43 fish examined
at 6 mpi/7 mpf, 28% fish showed “Small Belly” phenotype (Fig. 3A2, B2, C2), in which the
tumor size was relatively small and exhibited a mixture of hepatocytes with either transformed
basophilic features or near-normal eosinophilic features in histological evaluation (Fig. 3D2).
51% fish developed “Typical” tumor (Fig. 3A3, B3, C3), which were large, smooth tumors with
compact tissue organization (Fig. 3D3). 14% fish displayed tumor with “Hypervascular” phe-
notype (Fig. 3A4, B4, C4), which displayed prominent blood vessels overgrowth (Fig. 3D4).
Only 7% fish remained the “Ascites” phenotype with pseudoglandular organization of tumor
cells (Fig. 3A5–D5). Interestingly, these tumor phenotypes were related tomycAG expression
level. As shown in Fig. 3E, the “Hypervascular” tumors had the highestmycAG expression, fol-
lowed by the “Typical” and “Ascites” phenotypes, while the “Small” phenotype had the lowest
mycAG expression.
At 8 to 9 mpi, about 5% of fish developed multinodular HCC with cirrhosis similar to that
in humans (Fig. 4A–E). Although metastasis and tissue invasion were not observed in this mul-
tinodular HCC, loss of membrane-localized E-cadherin was observed (Fig. 4H,I), indicating in-
creased motility of tumor cells and possible preparation for epithelial-mesenchymal transition.
Moreover, increases of expression and nuclear translocation of β-catenin were also observed
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Figure 2. Rapid induction of live tumors by inducedmycAG expression.MycAG fish were induced with 2 μMmifepristone from 1 mpf and sampled at
10, 20 and 30 dpi for gross observation as indicated in the figure. (A1–A4) Gross observation of liver tumors after removal of abdominal wall. (B1–B4) The
same views as those in (A1–A4) for observation of GFP expression that illustrate the shape of livers. (C1–C4) H&E staining to show cellular alteration in the
fish liver. (D1–D4) PCNA staining by immunocytochemistry to show cell proliferation. (E1–E4) TUNEL assay to reveal the apoptosis in the liver. (F)
Quantitative analyses of cell proliferation and apoptosis. ## indicates highly significant difference (P<0.01) in proliferation when compared that in the Driver
Myc-Induced Liver Tumors in Transgenic Zebrafish
PLOS ONE | DOI:10.1371/journal.pone.0117249 January 22, 2015 5 / 17
(Fig. 4J,K), suggesting that another oncogenic signaling pathway, Wnt, had been activated in
the multinodular HCC.
Homozygous tp53M214Kmutation promotes tumor progression in mycAG
fish
Tp53 is a major tumor suppressor genes and its mutation has been detected in a majority of
human cancers [19]. To test the effect of tp53mutation on tumor progression in mycAG fish,
we introduced a tp53M214K homozygous mutation into this mycAG transgenic fish and named
this new line as AG53. Apparently, tp53M214K homozygous mutation significantly promoted
tumor progression in both adult (Fig. 5) and larval stages (S4A Fig.). As shown in Fig. 5, the
significant enlargement of belly of AG53 fish could be grossly observed as early as 0.5 mpi
when the mycAG fish had no apparent gross changes. The body size of AG53 fish was also sig-
nificantly smaller than mycAG fish, which may suggest a more serious tumor burden in AG53
fish. Differences were also manifested in histology, as shown in Fig. 5D1–D5. Although both
AG53 and mycAG fish were still similar in the features of basophilic cytoplasm, enlarged nuclei
and prominent eosinophilic nucleoli, the fast tumor progression in AG53 fish resulted in firm
and compact tumor type rather than the pseudoglandular tumor with ascites in mycAG fish at
1.5 mpi.
To investigate the effect of tp53M214K mutation, we first examined the levels of transgenic
mycAG and endogenousmyca expression in the Driver control, mycAG and AG53 fish, and
found both mRNAs were not affected by the mutation in AG53 fish (S4B Fig.). As many studies
have demonstrated that TP53 pathway plays an important role in Myc-caused apoptosis [18],
the effect of tp53M214K mutation on apoptosis was also examined. Apoptosis in the liver was
significantly reduced in AG53 fish when compared to that in the mycAG fish; however, it was
still higher than that in the Driver control that rarely had apoptosis signals (S4C Fig.). This ob-
servation suggested that tp53M214K mutation only blocked part of Myc-caused apoptosis, and/
or that some apoptosis pathways other than Tp53 may also be activated bymyca expression in
tumor progression. Collectively, these observations suggest that the acceleration of tumor pro-
gression in tp53M214K mutation was at least partially aided by the suppression of apoptosis.
Tumor state is dependent of sustained overexpression of transgenic
mycAG
One of the important features of the LexPR inducible expression system is the feasibility of in-
activation of transgenic expression by withdrawal of mifepristone [14]. To investigate the effect
of suppression of transgenic mycAG expression in both mycAG and AG53 fish, mifepristone
treatment was stopped at 6 mpi/7 mpf. As shown in Fig. 6E, the mRNA expression of transgen-
icmycAG in the liver greatly decreased within 8 days of mifepristone withdrawal (8 dpr, day
post-regression). At 18 dpr,mycAG level was comparable to the endogenousmyca expression
in the control fish liver. Consistently, GFP signal also faded away rapidly (Fig. 6, C2–C7). Only
very faint GFP was observed in mycAG and AG53 fish liver at 8 dpr (Fig. 6, C3 and C5) and es-
sentially no GFP could be detected at 18 dpr (Fig. 6, C4 and C7).
At 6 mpi, the AG53 liver tumor had a uniform tumor type with early HCC traits, while the
tumor histologic features in mycAG line fish were divergent, as mentioned earlier. With the re-
moval of mifepristone, the tumors shrunk fast in both mycAG and AG53 fish, while the body
control at 30 dpi; § and §§, indicate significant (P<0.05) and highly significant (P<0.01) difference respectively in apoptosis when compared to that in the
Driver control at 30 dpi.
doi:10.1371/journal.pone.0117249.g002
Myc-Induced Liver Tumors in Transgenic Zebrafish
PLOS ONE | DOI:10.1371/journal.pone.0117249 January 22, 2015 6 / 17
Figure 3. Diverse liver tumor phenotypes of mycAG zebrafish at 6 mpi.MycAG fish were induced by 2 μMmifepristone from 1 mpf and sampled at 7 mpf
(6 mpi) for gross observation and histological examination. Four phenotypes were observed: Small, Typical, Hypervascular and Ascites, as indicated at the
top of the figure with total numbers and percentages. (A1–A5) Exterior observation of each phenotype. (B1–B5) Gross observation of liver tumors after
removal of body wall. (C1 to C5) The same views as those in (B1–B5) for observation of GFP expression that illustrate the shape of livers. (D1–D5) H&E
staining of liver sections. (D1–D4) have the same magnification as indicated in scale bar in (D1). The scale bar in (D1) represents magnification for all of
(D1–D4) and blow-up area in (D5). (E) TransgenicmycAG expression in each phenotype. TransgenicmycAG expression in the liver was measured by RT-
qPCR and the level of expression was relative to baseline myca expression in the control Driver fish.
doi:10.1371/journal.pone.0117249.g003
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size and length increased significantly (Fig. 6, A2–A7). At the histological level, at just 8 dpr,
the neoplastic hepatocytes features observed earlier had been replaced by tissue characterized
by a relatively normal appearance with eosinophilic cytoplasm and basophilic nuclei (Fig. 6,
D3 and D6). At 18 dpr, the appearance of the cells (Fig. 6, D4 and D7) was already similar to
the Driver control (Fig. 6, D1). Moreover, cytoplasmic granules also increased in both mycAG
and AG53 fish hepatocytes during tumor regression, which was a sign of restoration of hepato-
cyte function. Previously we have observed a rapid increase of apoptosis during liver tumor re-
gression in our xmrk-induced liver tumors [20]. To examine whether apoptosis was involved
in tumor regression in tp53M214K background, TUNEL assay was carried out in the regression
Figure 4. Development of multinodular HCC in late stage of mifepristone induction.MycAG fish were induced by 2 μMmifepristone from 1 mpf and
sampled at 9 mpf (8 mpi) for gross observation, histological examination and immunocytochemistry. (A–D) Gross observation of multinodular HCC in two
examples of mycAG fish in both bright field and GFP channel. (E) Confocal microscope image to showGFP positive hepatocytes and GFP negative cirrhosis
stroma. (F,G) H&E staining of multinodular HCC sections with two different magnifications. (H,I) Immunocytochemical staining of E-cadherin in liver sections
from a Driver fish (H) and a mycAG fish (I). (J,K) Immunocytochemical staining of β-catenin in liver sections from a Driver fish (J) and a mycAG fish (K).
doi:10.1371/journal.pone.0117249.g004
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fish. Apoptosis was rare in control livers from the Driver fish (Fig. 7C), but increased with the
tumor progression in mycAG fish (Fig. 7A) and dramatically increased in the regression pro-
cess (Fig. 7B and 7F). As the normal liver has a very low level of apoptotic cells and there was a
decrease of GFP-labeled hepatocytes, it is likely that these apoptotic cells were mainly from
transformed hepatocytes, similar to the observation in tumor regression from xmrk oncogene
transgenic zebrafish [20]. Compared to the mycAG line fish, almost the same level of apoptosis
was also observed in AG53 fish liver tumor regression (Fig. 7E and 7F). Therefore, these obser-
vations indicated that some pathways other than p53 were also involved in apoptosis in the
process of tumor regression.
Figure 5. Accelerated liver tumor progression of mycAG fish in homozygous tp53M214K background (AG53).MycAG and AG53 fish were induced by
2 μMmifepristone from 1 mpf and sampled at 0.5 mpi and 1.5 mpi for gross observation and histological examination, as indicated at the top of the figure.
(A1–A5) Exterior observation of each phenotype. (B1–B5) Gross observation of liver tumors after removal of body wall. (C1 to C5) The same views as those
in (B1–B5) for observation of GFP expression that illustrate the shape of livers. (D1–D5) H&E staining of liver sections.
doi:10.1371/journal.pone.0117249.g005
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Figure 6. Tumor regression in mycAG fish and AG53 fish after mifepristone withdrawal.Mifepristone was withdrawn at 6 mpi (7 mpf), MycAG line and
AG53 fish were sampled at 0 dpr, 8 dpr and 18 dpr for gross observation and histological examination, (A1–A7) Exterior observation of each phenotype.
(B1–B7) Gross observation of liver tumors after removal of abdominal wall. (C1–C7) The same views as those in (B1–B5) for observation of GFP expression
that illustrate the shape of livers. (D1–D7) H&E staining of liver sections. Larger magnifications are shown in insets. (E) MycAGmRNA level in 0-dpr, 8-dpr
and 18-dpr liver samples as quantified by RT-qPCR. Each group had three biological replicates. # indicates significant difference (P<0.05) when compared
withmyca expression in the Driver.
doi:10.1371/journal.pone.0117249.g006
Myc-Induced Liver Tumors in Transgenic Zebrafish
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Discussion
Both Zebrafishmyca andmycb are Oncogenic in Hepatocytes
It is generally accepted that vertebrates underwent two rounds of whole genome duplication
during evolution from invertebrates and there was an additional round of teleost-specific
whole genome duplication about 350 Ma ago [21, 22]. Phylogenetic analysis of zebrafishmyc
family also indicated that two paralogs,myca andmycb, arose from a common ancestor in the
last whole genome duplication [23]. Although the expression of both of them are found in mi-
tosis hotspots in development [13], many differences exist between the two paralogs. For exam-
ple,myca is mainly expressed in brain whilemycb is in lateral line neuromasts [13]. In ciliary
marginal zone,myca and several other myc family genes are required in maintenance of con-
tinuous cell replacement; in contrast, nomycb expression is found in this process [24]. We also
found that themycb expression was much higher thanmyca in adult fish liver (S2A Fig.) and
their subcellular localization might be different too (S2B Fig.). All these findings suggested that
myca andmycb could have different physiological functions. However, overexpression of the
two myc genes in our transgenic models indicated that both have equivalent cellular function
in oncogenesis. The difference of severity of tumor induction between the two myc oncogenes
are likely due to the level of induced expression as we observed an increasing severity of tumor
Figure 7. Increase of apoptosis after mifepristone withdrawal.MycAG line and AG53 fish were induced by 2 μMmifepristone from 1 mpf and
mifepristone was removed after 6 month induction for tumor regression. These fish were then collected for TUNEL assay. (A–E) TUNEL assay for apoptosis
on liver sections from different types of fish at different time points as indicated. dpr, day post regression. (F) Quantification of apoptotic cells in liver sectons.
# and ## indicate significant difference with p-values of 0.05 and 0.01 respectively when compared to Driver at 0 dpr. § and §§ indicate significant difference
with p-values of 0.05 and 0.01 respectively when compared to Driver at 8 dpr.※ indicates significant difference (P<0.05) when compared with AG at 0 dpr.
doi:10.1371/journal.pone.0117249.g007
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progression from both mycAG and mycBG transgenic lines with increased mifepristone induc-
er, although the possibility thatmyca is more potent in ongogenesis thanmycb could not be
completely ruled out. It is also interesting to note that endogenousmycb expression was much
lower in induced mycAG fish than those in induced mycBG and Driver fish (S1A Fig.); this
could be due to a negative feedback control of endogenous myc expression by high level of
transgenic myc expression.
In the present study, we also found an apparent dosage-dependent induction of transgenic
myc expression, which in turn caused an increasing tumor severity (Fig. 1). A long time of in-
duction (up to 8 months) with 2 μMmifepristone caused essentially 100% mycAG fish to grow
liver tumors, among which, 5% of them had been confirmed to have multimodular HCC phe-
notype. The rest fish also showed some other malignant traits or signs of serious liver damage
(Fig. 3). For example, ascites itself is an important clinical syndrome in late stage human liver
cancer, and at the histological level, the compact hepatocytes organization in the “Typical” phe-
notype and neo-anginogenesis in the “Hypervascular” phenotype are also important properties
in human HCC. Therefore, though not confirmed as HCC, these induced mycAG fish did
show the deterioration and transition into malignant status.
Liver tumor progression in mycAG fish is accelerated by suppression of
apoptosis with tp53M214KMutation
It seems that different levels of mycAG expression also resulted in different tumor types, al-
though all the mycAG fish exhibited similar phenotypes at the early tumor stage (before 1
mpi), such as pseudoglandular tissue pattern and ascites (S3 and S4 Figs.). It was apparent that
sustained high level expression ofmyca was necessary in the development of advanced neo-
plasms in later stages. Myc provoked apoptosis has been observed in many studies [18] and we
also observed increased apoptosis in the liver tumor of mycAG fish (Fig. 2C1–C4). However,
HCC was still developed in our model eventually, suggesting that the oncogenicity of mycAG
fish is robust enough to overcome the apoptosis effect and to maintain the progression of ma-
lignant status. Moreover, it has also been found that in some tumor models, attenuating apo-
ptosis is necessary for successful malignant transformation [25, 26]. In this project we observed
that introducing a tp53M214K homozygous mutation which significantly suppressed apoptosis
could accelerate liver tumor progression.
Liver tumor regression does not require Tp53
Reversible neoplasms have been reported in antisense-treated human cancer cell lines and ani-
mal cancer models with conditional oncogene expression [27], including our previously re-
ported transgenic zebrafish models with inducible expression of Xiphophorus xmrk oncogene
and mouseMyc respectively [11, 20]. This phenomenon, i.e. malignant status dependency on
sustained activation of a specific oncogene, is named “oncogene addiction” [27]. Addiction to
Myc has also been reported in several previous studies. For example, in a tet-off mice acute my-
eloid leukemia model, introduction of doxycycline lead to suppression of transgenicMYC ex-
pression and caused regression of the tumor [28]. Similarly, in a Myc-induced mouse HCC
model, inactivation of transgenic Myc also caused rapid tumor regression with increased apo-
ptosis [29]. However, not all the tumors could regress after the elimination of the original onco-
genic factor, especially when additional oncogenic mutations have occurred, which is
essentially in all cases in human cancers. For example, the mammary adenocarcinoma in a
mouse model established byMYC overexpression could not regress after abolishingMYC ex-
pression because of a secondary spontaneous activating mutation in Kras [30].
Myc-Induced Liver Tumors in Transgenic Zebrafish
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In the mycAG and AG53 transgenic zebrafish reported here, inactivation of mycAG expres-
sion after removal of mifepristone resulted in rapid tumor regression in both groups of fish
and all the hepatocytes were reverted to a normal appearance histologically (Fig. 6). While it is
anticipated for a rise of apoptosis in mycAG fish during tumor regression, which is consistent
with several previous reports [20, 28], it is unusual to observe a similar increase of apoptosis in
AG53 fish. TP53 is a well-known tumor suppressor gene and a common function of Tp53 is to
induce apoptosis of damaged or tumorigenic cells for elimination [19]. It has been previously
reported for a Myc transgenic mouse model with hematopoietic tumors that tumor regression
by inactivation of transgenic Myc requires Tp53 as only incomplete tumor regression was ob-
served when Tp53 is lost [31]. In our AG53 fish model, although the homozygous tp53M214K
mutation could largely abolish apoptosis in the tumor progression stage (S4C Fig.), but it
seems that there was no effect during tumor regression. These observations suggested that the
malignant status of hepatocytes is addicted to sustained overexpression of zebrafishmyca but
tumor regression does not require the presence of Tp53. Since similar levels of apoptosis were
observed in both mycAg and AG53 fish during the initial stage of tumor regression, it is likely
that apoptosis during tumor regression is independent of the Tp53 pathway.
Material and Method
Generation of mycAG, mycBG and AG53 transgenic fish
This study involving zebrafish was carried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of
the National University of Singapore (Protocol Number: 096/12). All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. The
Liver-Driver line, Tg(fabp10:LexPR; LexA:EGFP), was generated in a previous study [14]. Two
Effector lines, Tg(cryB:mCherry; LexA:EGFP-myca) and Tg(cryB:mCherry; LexA:EGFP-mycb),
were generated in the present study using constructs depicted in S1 Fig. Both transgenic lines
were identified by visualization of mCherry expression in lens under the cryB promoter. To en-
hance genome integration, the Ac/Ds transposon system was adopted [32], in which, a DNA
construct was co-injected with in vitro transcribed transposase mRNA into zebrafish embryos
at the 1–2 cell stage. The injected embryos were then raised for founder screening and trans-
genic F1 were confirmed by mCherry expression. From the F1 generation, both effector lines
were maintained by crossing with the liver-driver fish and double transgenic fish were selected
based on mCherry expression in the lens (Effector) and constitutive GFP expression in the
liver (Driver). Multiplemyca andmycb effector transgenic lines were generated and they all
generated obvious liver tumors in early stages (S2F Fig.); in this study, we followed only one
transgenic line each of these myc genes and the double transgenic fish were named mycAG
and mycBG accordingly in this report.
The mycAG fish with tp53M214K homozygous mutation were generated by crossing mycAG
fish with a tp53M214K homozygous mutant fish [33]. The heterozygous offspring were raised by
incrossing and homozygosity for tp53M214K was selected by genotyping with PCR primer as in-
dicated in S1 Table [34]. The mycAG fish were then maintained in homozygous tp53M214K,
named AG53, by incrossing for experiments.
Mifepristone treatment
Mifepristone (RU-486, Sigma-Aldrich #M8046) was first dissolved in ethanol and diluted in
fish water for the final concentrations. The treatment was conducted in petri dishes or 6-L
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tanks at a density of ~50 larvae or ~25 adult per dish or tank, respectively. The water with mi-
fepristone was topped up every 3–4 days and totally changed every two weeks.
Reverse transcription-quantitative PCR (RT-qPCR)
Total RNA was extracted using TRIzol (Invitrogen #15596–018) and reverse-transcribed into
cDNA. To distinguish the endogenousmyca andmycbmRNAs from the transgenicmycAG
andmycBGmRNAs,myca andmycb primers were targeted at the coding region and 30 un-
translated regions whilemycAG andmycBG primers at the myc coding region and the GFP re-
gion. β-actin was used as an inner control. The primer sequences are presented in S1 Table.
Paraffin section and histological analyses
Fish samples were fixed in 10% neutral buffered formalin solution (Sigma, #HT5012). After de-
hydration and embedding with paraffin, sectioning was performed using a Leica microtome,
and all the samples were sectioned sagittally at a thickness of 4 μm. For ordinary observation,
the samples were stained with Hematoxylin (Sigma, #51275) and Eosin (Sigma, #HT110232).
For immunohistochemistry, the primary antibodies used were PCNA (AnaSpec Inc. #55421),
β-catenin (Abcam, #ab32572) and E-cadherin (Abcam, #ab1416). After washes with phosphate
buffered saline (PBS) with 0.1% Tween 20 (PBST) and incubation with appropriate secondary
antibody from the Dako Kit set (DAKO, Denmark, #346811), color was developed by using the
Liquid DAB & Substrate Chromogen system (DAKO, #346811). The slides were also conter-
stained with 5 μg/ml DAPI (40, 6-Diamidine-20-phenylindole dihydrochloride) to facilitate
nucleus observation.
TUNEL assay
TUNEL assay was conducted with ApopTag Plus In Situ Apoptosis Fluorescein Detection Kit
(Chemicon international, #S7111). After rehydration and treatment with 20 μg/ml proteinase
K in PBS at room temperature, the sections were treated with TDT enzyme and incubated with
alkaline phosphate-conjugated Anti-DIG. Next the slides were balanced in pH 9.5 buffer (0.1
M Tris-HCl/50 mMMgcl2/ 10 mMNaCl/0.1% Tween 20) and finally the signal colors were de-
veloped using nitro-blue tetrazolium/5-bromo-4-chloro-30-indolyphosphate in pH 9.5 buffer.
Statistical analyses
T-test was used for all assays in the present studies, including cell counting in DOPI, PCNA
and TUNEL staining, measurement of 2D liver size and RT-qPCR. Statistical significance was
indicted in figure legends.
Supporting Information
S1 Fig. Schematic representation of DNA constructs used in the mifepristone-inducible ex-
pression system. The mifepristone inducible expression system has been described previously
[14, 15]. The Driver construct consists of a chimeric LexPR transcription activator under the
liver-specific fabp10a promoter. The driver construct also contains an EGFP effector transcrip-
tion unit under the LexA operator. Two effector constructs for expression ofmyca andmycb
under the LexA operator were also made. The effector constructs also contain an mCherry re-
porter gene under a lens-specific crybb promoter for identification of effector fish. Both the
driver and effector constructs are flanked with transposon Ds elements for improving of effi-
ciency of genome insertion [32].
(PDF)
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S2 Fig. Effects ofmycAG andmycBG expression in zebrafish liver. (A) Expression of trans-
genicmycAG andmycBG in comparison with expression of endogenousmyca andmycb genes.
Liver RNA from 1 mpi (2 mpf) fish treated with 2 μMmifepristone were analysed by RT-qPCR
and expression values are relative to the level of endogenousmycamRNA, which is arbitrarily
set as 1. (B) Subcellular localization of mycAG and mycBG fusion proteins. Fish were all treated
with 2 μMmifepristone and liver tissues were collected at 1 mpi (2 mpf) for cryosection. GFP
signal was recorded by confocal microscope with the same exposure time. Nuclei were stained
by DAPI and recorded in the blue channel. Wild type liver was used as a negative control.
(C) Dosage-dependent effect of mifepristone induction on GFP or Myc-GFP expression and
liver size in Driver, mycAG and mycBG larvae. These transgenic fish were induced with mifep-
ristone at different concentrations from 3 dpf and photographed at 8 dpi (5 dpi). (D) Dosage-
dependent increase ofmycAG andmycBG expression as measured by RT-qPCR. (E) Quantifi-
cation of liver size based on 2D images at 4 μMmifepristone. Size of liver of larvae was mea-
sured according to GFP signal area. # and ## indicate significant difference with p-values
of 0.05 and 0.01 respectively when compared with the liver size in the Driver. (F) Induction of
liver tumors from other mycAG transgenic families. Representative fish from three other
mycAG transgenic families are shown with gross observations of liver tumors (upper
panels) and GFP expression (lower panels) to illustrate the liver tissues as described in
Fig. 1B and 1C.
(TIF)
S3 Fig. Ascites in mycAG zebrafish.MycAG fish were induced by 2 μMmifepristone from
1 mpf and sampled at 7 mpf (6 mpi) for gross observation and histological examination. (A)
Gross observation of the mycAG fish with ascites phenotype in monotone background. (B)
Gross observation of the same fish in (A) under a dark background to show transparent belly.
(C) H&E staining of the fish presented in (A,B). (D, E) Isolated liver tumor from another
mycAG fish with ascites for GFP view (D) and for view in a dark background to show transpar-
ent, foam-like structure (E). Liquid was observed in cysts in the liver. (F) H&E staining of the
liver tumor presented in (C,D).
(PDF)
S4 Fig. Reduction of apoptosis and acceleration of liver tumor progression in mifepris-
tone-induced mycAG fish with tp53M214Kmutation (AG50). (A) Comparison of liver size be-
tween mycAG and AG53 larvae. Larvae were induced with 2 μMmifepristone from 3 dpf and
photographed at 5 dpi (8 dpf). Liver size was measured based on 2D GFP images as previously
described [35]. ## and # indicate significant difference with p-values of 0.01 and 0.05 respec-
tively when compared with the liver size in the Driver53 (Driver fish in tp53M214K mutation
background). §§ and § indicate significant difference with p-values of 0.01 and 0.05 respective-
ly when compared with the liver size in the Driver. ++ indicates significant difference (P<
0.01) when compared with the liver size in AG53. (B) Induction ofmycAG expression in
mycAG and AG53 fish. Total RNA was extracted from 5 dpi/8 dpf larvae treated with 2 μMmi-
fepristone for RT-qPCR analyses. Each group has three biological replicates and there was no
significant effect on induction ofmycAGmRNA by tp53M214K mutation. # indicates the expres-
sion differences when compared to endogenousmyca expression in Driver fish (p< 0.05). (C)
Apoptosis in AG53 and mycAG fish livers. Liver sections from 2 mpi (3 mpf) driver, mycAg
and AG50 fish were used for TUNEL staining. Each group has 3 to 4 biological replicates and
apoptosis was counted and represented in column. ##, indicates the difference in proliferation
when compared with Driver is significant (P< 0.01). §§ indicates significant difference be-
tween mycAG and AG50 fish (P< 0.01).
(PDF)
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S1 Table. Primer Sequences Used in PCR.
(DOCX)
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